Tricaprylin

Data from the pilot study in infantile spasms showed positive outcomes. The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's partnering discussions. DENVER, Aug. 29, 2023 /PRNewswire/ -- Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, today announced that new data on investigational CER-0001 (tricaprilin) in infantile spasms (also known as West syndrome) has been accepted for presentation at the 35th International Epilepsy Congress, held in Dublin, Ireland from September 2nd-6th 2023. The data will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon. The presentation title is, "Treatment of Drug-Resistant Infantile Spasms with CER-0001, A Ketogenic Agent: Preliminary Results". Following the presentation, the materials will be available to view in full at: The trial was an open label pilot study conducted in Australia and Singapore to evaluate the safety and tolerability of CER-0001 for treatment of drug-resistant infantile spasms. Eight patients were enrolled and the dose of CER-0001 was titrated up from 7 to 14 days, followed by a maintenance period of 7 days. CER-0001 was well tolerated in the trial with the most common adverse events being gastrointestinal in nature. As observed on the video electroencephalogram, 50% of subjects enrolled had ≥50% improvement of seizure clusters and 25% of subjects had complete resolution of spasms. The study was registered on clinicaltrials.gov (NCT04727970). Subjects in Australia with a clinical benefit at the end of the maintenance period were allowed to continue in a 1-year open label extension. CER-0001 is an investigational oral small-molecule that is believed to act as a precursor to ketone bodies to increase plasma ketone levels. Many studies have shown that the ketogenic diet may reduce or prevent seizures in children whose seizures could not be controlled by anti-seizure medications. Infantile spasms usually affects children under the age of 36 months and can lead to permanent cognitive, neurologic and sensory problems. The disorder is commonly treated with hormonal medications (such as adrenocorticotropic hormone and prednisolone) and vigabatrin, an anticonvulsant. Both interventions have a burden of monitoring and a significant risk of serious adverse events, hence the need for new therapies that can improve the treatment experience for patients and caregivers. Cerecin's infantile spasms program has received rare paediatric disease designation, orphan drug designation and clearance to study CER-0001 under an Investigational New Drug (IND) from the US FDA, as well as orphan drug designation from the EMA. Dr. Marc Cantillon commented, "We are pleased by our continued progress in developing CER-0001 in epilepsy. This data supports our further investigation of CER-0001 in the treatment of infantile spasms and potentially also in other paediatric seizure disorders where few or no options are available. Planning is already underway for our next study in infantile spasms and other developmental and epileptic encephalopathies". At the International Epilepsy Congress, the Cerecin team will be accompanied by PharmaVentures, a transaction advisory firm, who will be supporting Cerecin's partnering discussions. The Cerecin team will be having meetings with potential partner companies. Infantile spasms Infantile spasms, also known as West Syndrome in other geographies, is a severe, ultra-rare form of epilepsy that affects infants under the age of 36 months. Incidence is estimated at approximately 2,000 new cases in the U.S. per year, which can be classified as an ultra-orphan disease. Infantile spasms patients experience rapid, characteristic muscular contraction or extensions lasting one to two seconds and occurring in clusters ranging from a few spasms to more than 100 spasms per cluster. These epileptic spasms occur along with hypsarrhythmia and developmental stagnation or regression. About Cerecin Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY) and Wilmar International Limited (SGX: F34), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its leadership team, Cerecin is becoming a global leader in bioenergetics and neurometabolism. About CER-0001 (tricaprilin) CER-0001 (tricaprilin) is an investigational drug being developed by Cerecin for various neurological indications, including Alzheimer's disease, migraine, and rare epilepsies. CER-0001 is a ketogenic compound and is intended to leverage the numerous activities and benefits of ketone bodies. The safety and efficacy of CER-0001 have not been established. Forward looking statements: This press release contains "forward-looking statements" under applicable securities laws that are based on the current expectations and beliefs of Cerecin. Such statements may be accompanied by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "possible," "will" and other words and terms of similar meaning. All statements, except for statements of historical fact, are statements that could be deemed forward- looking statements, including but not limited to: (i) sources and availability of third party financing and investments and the projected financial performance of the Company; (ii) the expected development of the Company's business, projects, drug development programs and joint ventures; (iii) execution of the Company's vision and growth strategy, including with respect to future growth; and (iv) new developments with respect to the Company's projects that are currently underway, in development or otherwise under consideration. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Forward-looking statements are not guaranties of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of Cerecin believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Cerecin undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. For more information visit . For further information, please contact: [email protected] © 2023 Cerecin AC-23-972 SOURCE Cerecin

Gundry MD MCT Wellness Helps Users Maintain High Energy Levels, A Healthy Metabolism, and Mental Sharpness LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- August is National Wellness Month, a time dedicated to prioritizing our well-being and making conscious efforts to improve our overall health. As we focus on enhancing our wellness, incorporating a dietary supplement into our routine can play a key role in helping achieve optimal vitality. Continue Reading Gundry MD MCT Wellness is a revolutionary dietary supplement that delivers MCT (medium-chain triglycerides) to the liver. This groundbreaking dietary supplement also helps maintain a healthy weight, facilitates smoother digestion, and helps enhance mental sharpness. Dr. Steven Gundry, a pioneer in nutrition and a world-renowned heart surgeon, highly recommends incorporating a supplement like Gundry MD™ MCT Wellness into your daily routine. This groundbreaking supplement offers multiple benefits crucial to overall well-being. It can not only aid in maintaining a healthy weight and promoting smoother digestion but can also help enhance mental sharpness. The formula is thoughtfully designed with a potent blend of MCT oil and powerful nutrients, including polyphenols. These components work synergistically to support heightened activity, boost metabolism, and enhance brain health. With its two delightful flavors, watermelon lemonade, and raspberry medley, Gundry MD MCT Wellness is an excellent addition to daily routines, making the pursuit of wellness in honor of National Wellness Month a truly enjoyable and satisfying experience.†* What is Gundry MD MCT Wellness? Gundry MD MCT Wellness is a revolutionary dietary supplement designed to provide your body with MCT (medium-chain triglycerides). These MCTs directly reach the liver and are converted into ketones, which play a crucial role in supporting your brain, mitochondrial health, and metabolism. Gundry MD MCT Wellness stands out with its unique combination of caprylic acid and bioflavonoids. This blend enhances the absorption and utilization of MCTs, leading to higher levels of fat-burning ketones that aid in weight management support. This ground-breaking supplement's bioflavonoids are sourced from grape seed and currant extracts, which expedite the transportation of ketones throughout the body. As a result, users can experience the potent benefits of ketones more rapidly, leading to a noticeable and faster impact on overall well-being. Gundry MD MCT Wellness' potent formula also contains polyphenols, contributing to a healthy and vibrant complexion, helping promote smoother digestion, supporting weight loss efforts, and sustaining energy levels. Overall, Gundry MD MCT Wellness is a powerful and comprehensive supplement that supports various aspects of your health, ensuring you can lead a more vibrant and energetic life.†* What Are The Key Ingredients in Gundry MD MCT Wellness?†* C8 MCT Oil (medium-chain triglycerides) and Acacia Fiber: these ingredients work together to support and maintain your body's ketone levels, ultimately promoting a sustained boost in energy. Bioflavonoids: derived from Grape Seed Extract, Red Currant, and Black Currant, these bioflavonoids play a crucial role in supporting the production of nitric oxide, which facilitates faster transportation of ketones throughout the body, helping ensure a more efficient and effective energy metabolism. The Suggested Use of Gundry MD MCT Wellness To achieve the best possible outcomes, it is advised to blend one scoop of Gundry MD MCT Wellness raspberry medley or watermelon lemonade with 10 ounces of water daily. Enjoy these delightful flavors not only with water but also in various beverages like nut milks, coffee, tea, and more, tailoring it to your personal taste preferences. Whether with or without a meal, the easily digestible formula of Gundry MD MCT Wellness allows for hassle-free consumption. For more detailed information about Gundry MD MCT Wellness, a special informational video is available on the Gundry MD YouTube Page, providing valuable insights into the product's benefits and usage. Where to Purchase Gundry MD MCT Wellness? Gundry MD MCT Wellness Raspberry Medley and Watermelon Lemonade can be purchased on for the price of $79.95 for a 30-day supply with a 90-day purchase price guarantee. About Gundry MD Founded in 2015, Gundry MD is dedicated to providing cutting-edge solutions to its users by using science-backed ingredients that can offer a boost in metabolism, all-day energy, smooth, easy digestion, and a youthful-feeling mind and body. These amazing results all begin with feeding your body powerful health-boosting nutrients like polyphenols. Based on his many years of nutrition research, Dr. Gundry helps create every Gundry MD product. Best-selling Gundry MD products include Total Restore, Energy Renew, and Polyphenol-Rich Olive Oil. All Gundry MD products come with a 90-day purchase price guarantee if you are not satisfied. For more information, visit or @gundrymd on Instagram and Facebook. About Dr. Gundry Founder of Gundry MD, Dr. Steven Gundry is a pioneer in nutrition and one of the world's top cardiothoracic surgeons, as well as medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Beverly Hills, Palm Springs, and Santa Barbara, California. He has spent the past 25 years helping people restore their health by optimizing nutrition and lifestyle choices. Steven Gundry MD is also the host of the health podcast, The Dr. Gundry Podcast, and author of four New York Times best-selling books including The Plant Paradox™ which details his famous lectin-free or Plant Paradox diet. For more information, visit , the Dr. Gundry YouTube channel, @drstevengundry on Instagram, and @drgundry on TikTok. *All individuals are unique. Your results can and will vary. †These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Press contact: Ashley Beenen [email protected] SOURCE Gundry MD